

This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the Japanese original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

Securities code: 4547

June 25, 2024

To Shareholders:

Mutsuo Kanzawa
Chairman & CEO
KISSEI PHARMACEUTICAL
CO., LTD.
19-48, Yoshino, Matsumoto City,
Nagano, Japan

**NOTICE OF RESOLUTIONS OF
THE 79th ANNUAL GENERAL MEETING OF SHAREHOLDERS**

Dear Shareholders:

We would like to express our appreciation for your continued support and patronage.

We hereby inform you that reports and resolutions were made at the 79th Annual General Meeting of Shareholders of KISSEI PHARMACEUTICAL CO., LTD. (the “Company”) as described below.

Matters reported:

1. The Business Report and Consolidated Financial Statements for the Company’s 79th Fiscal Year (April 1, 2023 - March 31, 2024) and results of audits by the Accounting Auditor and the Audit & Supervisory Board of the Consolidated Financial Statements
2. Non-consolidated Financial Statements for the Company’s 79th Fiscal Year (April 1, 2023 - March 31, 2024)

The above two matters were reported.

Matters resolved:

Proposal 1: Appropriation of Surplus

The proposal was approved and adopted as originally proposed, and the amount of the year-end dividend was decided to be ¥41 per share.

Proposal 2: Partial Amendments to the Articles of Incorporation

The proposal was approved and adopted as originally proposed.

Proposal 3: Election of Twelve (12) Members of the Board

The proposal was approved and adopted as originally proposed. Mr. Mutsuo Kanzawa, Mr. Yasuo Takehana, Mr. Keiji Fukushima, Mr. Tetsu Takayama, Mr. Takahide Kitahara, Mr. Yoshio Furihata, Mr. Hiroshi Noake, Mr. Keiji Miyazawa, Mr. Shigetaka Shimizu, Mr. Minoru Nomura, Ms. Sayuri Uchikawa and Mr. Yoshinori Otsuki were re-elected as Members of the Board and assumed their respective offices.

Proposal 4: Election of Two (2) Audit & Supervisory Board Members

The proposal was approved and adopted as originally proposed. Mr. Michio Iwabuchi was re-elected and Ms. Naomi Koshihara was newly elected as Audit & Supervisory Board Members and assumed their respective offices.

Proposal 5: Election of One (1) Substitute Audit & Supervisory Board Member

The proposal was approved and adopted as originally proposed. Mr. Akio Kubota was elected as Substitute Audit & Supervisory Board Member.

Proposal 6: Bonus Payments to Members of the Board

The proposal was approved and adopted as originally proposed. It has been decided that bonus payments to Members of the Board in the aggregated amount of ¥9,550,000 will be paid for eight (8) Members of the Board (excluding Outside Directors) at the end of the fiscal year under review.

End

Notice

The Representative Directors and the Executive Directors were elected as follows and assumed their respective offices at the Board of Directors' meeting held after the conclusion of the Annual General Meeting of Shareholders.

Chairman & CEO	Mutsuo Kanzawa
President & COO	Yasuo Takehana
Executive Vice President	Keiji Fukushima
Executive Managing Director	Tetsu Takayama
Managing Director	Takahide Kitahara
Senior Advisor, Member of the Board	Yoshio Furihata

In addition, Mr. Shinji Kikuchi and Ms. Naomi Koshihara were elected as Full-time Audit & Supervisory Board Members and assumed their respective offices at the Audit & Supervisory Board meeting held after the conclusion of the Annual General Meeting of Shareholders.